Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy
The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete \>1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). These participants are at high risk for progression of kidney disease, which can result in end-stage renal failure.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Clinical Trial Site
Vancouver, British Columbia, Canada
Clinical Trial Site
Brampton, Ontario, Canada
Clinical Trial Site
Toronto, Ontario, Canada
Clinical Trial Site
Grenoble, France
Clinical Trial Site
La Tronche, France
Clinical Trial Site
Mulhouse, France
Clinical Trial Site
Kuala Lumpur, Malaysia
Clinical Trial Site
Kuantan, Malaysia
Clinical Trial Site
Serdang, Malaysia
Clinical Trial Site
Quezon City, Philippines
Start Date
September 30, 2019
Primary Completion Date
March 17, 2022
Completion Date
June 27, 2023
Last Updated
August 9, 2024
31
ACTUAL participants
Placebo
DRUG
Cemdisiran
DRUG
Lead Sponsor
Alnylam Pharmaceuticals
NCT05510323
NCT07445906
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07022574